Supernus Pharmaceuticals Reiterates FY24 Revenue $580M-$620M Vs $601.461M Est.
Portfolio Pulse from Benzinga Newsdesk
Supernus Pharmaceuticals has reaffirmed its fiscal year 2024 revenue forecast to be in the range of $580 million to $620 million, which is in line with the analyst estimate of $601.461 million.
May 08, 2024 | 9:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Supernus Pharmaceuticals reaffirms its FY24 revenue guidance, aligning with analyst expectations.
Reiterating a revenue forecast that aligns with analyst expectations generally instills confidence in investors about the company's financial health and future prospects. This announcement is likely to have a positive impact on SUPN's stock price in the short term as it reassures investors of the company's stability and growth trajectory.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100